title: Expression of a dominant negative mutant of interleukin-1 beta converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury.
abstract: To explore the role of the interleukin (IL)-1 beta converting enzyme (ICE) in neuronal apoptosis, we designed a mutant ICE gene (C285G) that acts as a dominant negative ICE inhibitor. Microinjection of the mutant ICE gene into embryonal chicken dorsal root ganglial neurons inhibits trophic factor withdrawal-induced apoptosis. Transgenic mice expressing the fused mutant ICE-lacZ gene under the control of the neuron specific enolase promoter appeared neurologically normal. These mice are deficient in processing pro-IL-1 beta, indicating that mutant ICEC285G blocks ICE function. Dorsal root ganglial neurons isolated from transgenic mice were resistant to trophic factor withdrawal-induced apoptosis. In addition, the neurons isolated from newborn ICE knockout mice are similarly resistant to trophic factor withdrawal-induced apoptosis. After permanent focal ischemia by middle cerebral artery occlusion, the mutant ICEC285G transgenic mice show significantly reduced brain injury as well as less behavioral deficits when compared to the wild-type controls. Since ICE is the only enzyme with IL-1 beta convertase activity in mice, our data indicates that the mutant ICEC285G inhibits ICE, and hence mature IL-1 beta production, and through this mechanism, at least in part, inhibits apoptosis. Our data suggest that genetic manipulation using ICE family dominant negative inhibitors can ameliorate the extent of ischemia-induced brain injury and preserve neurological function.
authors.affiliation: Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Charlestown 02129, USA.
authors.forename: R M
authors.initials: RM
authors.lastname: Friedlander
authors.forename: V
authors.initials: V
authors.lastname: Gagliardini
authors.forename: H
authors.initials: H
authors.lastname: Hara
authors.forename: K B
authors.initials: KB
authors.lastname: Fink
authors.forename: W
authors.initials: W
authors.lastname: Li
authors.forename: G
authors.initials: G
authors.lastname: MacDonald
authors.forename: M C
authors.initials: MC
authors.lastname: Fishman
authors.forename: A H
authors.initials: AH
authors.lastname: Greenberg
authors.forename: M A
authors.initials: MA
authors.lastname: Moskowitz
authors.forename: J
authors.initials: J
authors.lastname: Yuan
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000502:physiology*; D001921:Brain / Q000098:blood supply / Q000473:pathology; D002545:Brain Ischemia / Q000473:pathology / Q000503:physiopathology; D020170:Caspase 1; D002452:Cell Count; D002490:Central Nervous System / Q000502:physiology*; D002536:Cerebral Arteries / Q000601:surgery; D002642:Chick Embryo; D003546:Cysteine Endopeptidases / Q000235:genetics*; D015853:Cysteine Proteinase Inhibitors / Q000235:genetics*; D005154:Facial Nerve / Q000166:cytology; D005727:Ganglia, Spinal / Q000473:pathology / Q000502:physiology; D008070:Lipopolysaccharides / Q000494:pharmacology; D051379:Mice; D018345:Mice, Knockout; D008817:Mice, Mutant Strains; D008822:Mice, Transgenic; D009046:Motor Neurons / Q000166:cytology; D009154:Mutation; D009414:Nerve Growth Factors / Q000172:deficiency; D009419:Nerve Tissue Proteins / Q000172:deficiency; D009474:Neurons / Q000473:pathology / Q000502:physiology; D011499:Protein Processing, Post-Translational
chemical_list: D015853:Cysteine Proteinase Inhibitors; D008070:Lipopolysaccharides; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D003546:Cysteine Endopeptidases; D020170:Caspase 1